|
Patent landscape, scope, and claims: |
Patent 7,842,687 Scope and Claims for Purified, Low-Impurity n=2/n=3 Crystalline Compounds: What This Estate Protects in the US and How It Limits Generic Entry
United States Patent 7,842,687 is an impurity-specification and solid-state-identity patent. Its independent claim set is built around (i) a defined chemical scaffold for n=2 or n=3, (ii) strict impurity totals plus a major impurity cap, (iii) chromatographic assay thresholds (claim 1), and (iv) for crystalline embodiments, binding solid-state fingerprints by DSC, X-ray diffractogram, and IR spectra at KBr (claims 4–9). Downstream protection extends to pharmaceutical compositions and therapeutic methods spanning parasitic disease, immunosuppression, and leukemia (with AML, MDS and myeloproliferative disorders, including chronic myelogenous leukemia), plus multiple routes of administration (parenteral including subcutaneous, oral, anal, topical).
The estate’s enforceability against generics typically depends on whether the generic product can meet the same impurity and assay limits and, for solid forms, whether its polymorph/solvate matches the cited DSC/XRD/IR profiles “substantially the same” as the patent figures. That structure gives the patentee strong leverage in manufacturing and analytical disputes rather than broad “composition-of-matter” coverage untethered from critical quality attributes.
What is US Patent 7,842,687 claiming: purified low-impurity n=2/n=3 compounds and crystalline solid forms?
Short answer: The core claim is to a purified compound defined by structure (n=2 or n=3) and quantified by impurity limits and chromatographic assay. Additional claims narrow to crystalline polymorphs by requiring substantially the same DSC, X-ray diffractogram, and IR spectra as specific figures.
What does claim 1 cover (scope center of gravity)
Claim 1 recites:
- A purified compound of “the following formula” with n = 2 or n = 3.
- Total impurities < 1% (explicit).
- Total impurities such that major impurity < 0.9% (explicit).
- Chromatographic assay of purified compound > 97.5% (explicit).
Practical scope impact
- Claim 1 is not satisfied by “made by any purification method.” It is satisfied only if the finished material meets the measured analytical thresholds at relevant testing conditions.
- The claim is quality-attribute driven, which can create “non-infringement by spec” opportunities for generics using different purification trains or different starting material profiles that yield analytically different impurity distributions, even if the API has the same molecular structure.
What do dependent claims 2 and 3 add?
- Claim 2: n = 3.
- Claim 3: n = 2.
This converts the undifferentiated “n=2 or n=3” into two narrower claim lanes, useful for claim charts that match a competitor’s exact analog.
What do claims 4–9 protect: crystalline identity by DSC/XRD/IR
Claims 4–9 add a solid-state limitation: the compound must be purified crystalline and have substantially the same thermal/structural/spectroscopic fingerprints as shown in specified figures:
- Claim 4: substantially the same DSC curve as FIG. 1.
- Claim 5: substantially the same X-ray diffractogram as FIG. 2 and substantially the same IR spectrum (KBr) as FIG. 3.
- Claim 6: combination of DSC FIG. 1 + XRD FIG. 2 + IR KBr FIG. 3.
- Claim 7: substantially the same DSC curve as FIG. 4.
- Claim 8: substantially the same IR (KBr) as FIG. 5.
- Claim 9: combination of DSC FIG. 4 + IR FIG. 5 (no XRD in claim 9 as written).
Practical scope impact
- These are not generic “crystalline form” claims; they are tethered to specific reference fingerprints.
- “Substantially the same” invites expert and laboratory-method scrutiny: detector resolution, baseline correction, sample preparation, hydration state, particle size effects, and instrument calibration can matter.
What do claims 10–11 add: tautomers, salts, and enantiomeric impurity definition
- Claim 10: purified compound includes tautomeric forms and salts thereof.
- Claim 11: purified compound is an enantiomer, and the “total content of impurities includes the other enantiomeric forms.”
Practical scope impact
- Claim 11 aligns impurity definition with stereochemical purity: a generic that produces a mixture with elevated opposite-enantiomer content can fail the “total impurities” and “major impurity” caps even if it hits chromatographic assay and total impurity totals are measured differently.
How broad are the composition-of-matter vs composition-of-therapy protections in 7,842,687?
Short answer: The patent covers (i) API material defined by analytical specs, (ii) crystalline polymorphs defined by DSC/XRD/IR identity, (iii) pharmaceutical compositions containing those materials, and (iv) therapeutic method-of-use for parasitic disease, immunosuppression, and leukemia across routes.
Pharmaceutical composition claims 12–18
- Claim 12: pharmaceutical composition containing effective amount of purified compounds of claim 1 + pharmaceutically acceptable inactive component.
- Claim 13: inactive component can be carriers/excipients/adjuvants/diluents.
- Claims 14–15: compositions for claim 2 and claim 3 variants (n=3 and n=2).
- Claims 16–18: compositions using crystalline embodiments of claims 5, 6, and 9, respectively.
Scope impact
- These composition claims are structurally broad on excipients but narrow on what API qualifies (must meet claim 1 or crystalline identity claim elements, depending on the claim).
- Generic formulations face the same spec/polymorph risks as API claims unless the generic can establish non-infringement at the analytical level.
Method claims 19–29 (treatment + route)
- Claim 19: parasitic disease treatment.
- Claim 20: immunosuppressive therapy.
- Claim 21: leukemia treatment.
- Claim 22: leukemia selected from AML, MDS, and myeloproliferative disorders.
- Claim 23: myeloproliferative disorder = chronic myelogenous leukemia.
- Claim 24: adjuvant therapy of resistance to other chemotherapeutic agents.
- Claims 25–28: parenteral, oral, anal, topical modes.
- Claim 29: parenteral specifically subcutaneous.
Scope impact
- This is method-of-use claim protection. It does not directly block a generic “selling the drug” unless the claimed use is covered by the patent and the generic’s label or prescribing practices implicate the claim.
- In US practice, enforcement often targets product labeling or off-label practice evidence, which depends on regulatory labeling status.
What patents protect the same impurity-specification concept: how would 7,842,687 be used in infringement theories?
Short answer: US 7,842,687’s claims structure supports infringement theories centered on analytical comparability (impurity totals/major impurity, assay > 97.5%), and for crystalline forms, “fingerprint” identity (DSC/XRD/IR match to figures).
Typical infringement map under these claims
- Identify the generic API identity (n=2 or n=3; enantiomer; tautomer/salt).
- Test impurity profile: total impurities, major impurity fraction, and chromatographic assay.
- If crystalline product is used, compare DSC/XRD/IR against the reference figure(s) named in claims 4–9.
- For method claims, tie the approved or marketed use to the claimed disease category and administration route (claims 19–29).
Strength drivers and weak points
- Strong drivers:
- Explicit numeric thresholds (impurity total <1%, major impurity <0.9%, assay >97.5%) are measurable and often hard to “argue around.”
- Crystalline fingerprinting is specific to figures, limiting breadth to particular solid states.
- Weak points:
- If the competitor’s material is the same API but fails one threshold (e.g., impurity major fraction slightly above 0.9% or assay below 97.5%), non-infringement becomes a lab question.
- “Substantially the same” allows maneuver via instrument conditions and differences in sample preparation, though that often cuts both ways during litigation.
When does US 7,842,687 lose exclusivity: what is the expiration timeline under US patent terms?
No expiration or legal status can be derived from the claim text alone. A complete timeline requires the application/filing date, priority date, patent term adjustments, and any terminal disclaimers or later regulatory exclusivity overlays. Without those data, a correct exclusivity and expiration schedule cannot be produced here.
What is the Orange Book status of the US 7,842,687-protected drug?
No drug name, NDA/BLA number, or listing identifiers are provided in the prompt, so Orange Book status cannot be determined from the patent number and claim text alone.
Which generic entry risks exist for products seeking FDA approval under Paragraph IV when claims look like this?
Short answer: The highest practical risk for generic applicants is failure to replicate the patentee’s critical impurity/assay profile and, for crystalline products, failure to match the DSC/XRD/IR fingerprints “substantially the same” as the named figures.
Risk profile by claim type
- Claim 1 impurity-spec risk: generics often can control assay, but controlling impurity distribution to exact caps is harder. The “major impurity” framing can become the key battleground.
- Claims 4–9 crystalline identity risk: polymorphic control is non-trivial. If a competitor uses a different form that still contains the same API but yields different DSC/XRD/IR profiles, those crystalline claims may be avoided.
- Method claims risk: label design and intended use matter. If the innovator’s labeling covers parasitic disease, immunosuppression, and leukemia with specified routes, method claims become more enforceable. If generic labeling is carved out, the method claim risk can decline.
How does 7,842,687 compare with typical US composition patents: is it narrow or broad?
Short answer: Narrow on chemical quality and solid-state identity, broad on therapeutic coverage categories and route of administration.
Composition scope
- Narrow:
- Purification is defined by analytics, not by general “purified process.”
- Crystalline embodiments are defined by figure-based DSC/XRD/IR matching.
- Broader than many impurity patents:
- Claim 10 and claim 11 expand to tautomers/salts and enantiomeric framing, which can broaden infringement reach if the generic makes a closely related derivative but still falls within those definitions.
Method scope
- Broad:
- Disease categories include parasitic disease, immunosuppression, and leukemia.
- Routes include oral, parenteral (subcutaneous specified), anal, topical.
What litigation issues are most likely with this claim set (analytics, polymorph control, and label-use)?
Short answer: This patent’s claim language pushes disputes toward (i) lab method differences for impurity/assay quantification and (ii) expert testimony on “substantially the same” spectral/thermal fingerprints and on whether marketing and prescribing practices implicate the method claims.
Analytics disputes likely include
- Definition and measurement of:
- “Total content of impurities,” including whether enantiomeric impurity counts as “impurities” as framed by claim 11.
- “Major impurity” identification and quantification method.
- Chromatographic assay thresholds and system suitability under claim 1.
Solid-state disputes likely include
- Sample prep and conditioning (wet vs dried, hydration/dehydration, grinding effects).
- DSC parameters (scan rate, thermal history).
- XRD measurement settings and whether amorphous content or mixed phases appear.
- IR KBr pellet preparation effects.
Patent landscape: what other US filings would commonly surround a spec-defined crystalline impurity patent like 7,842,687?
Short answer: In portfolios that use impurity caps plus DSC/XRD/IR identity, related assets often include:
- Process patents for purification to hit <1% total impurities and <0.9% major impurity.
- Additional polymorph patents with different figure references.
- Formulation patents focusing on excipient choices, particle size, dissolution, or stable amorphous/crystalline mixtures.
- Regulatory/label use continuation patents when therapeutic indications expand.
No itemized landscape can be listed here because the prompt does not provide the API identity (chemical name/structure) or any family member identifiers (priority application, assignee, related publication numbers).
Key Takeaways
- US 7,842,687 protects an API defined as n=2 or n=3 with tight analytical quality attributes: total impurities <1%, major impurity <0.9%, and chromatographic assay >97.5% (claim 1).
- It separately protects crystalline solid forms using figure-referenced DSC/XRD/IR “substantially the same” comparisons (claims 4–9).
- It extends to pharmaceutical compositions containing qualifying purified or crystalline APIs (claims 12–18).
- It extends to method-of-use claims for parasitic disease, immunosuppression, and leukemia (with AML, MDS, and myeloproliferative disorders including chronic myelogenous leukemia) across multiple routes, including subcutaneous (claims 19–29).
- The most direct generic entry threat is failing the impurity/assay specifications or using a different polymorph that does not match the DSC/XRD/IR figures.
FAQs
- What does “major impurity <0.9%” practically require for infringement under claim 1?
- Can a generic avoid claims 4–9 by marketing a different polymorph even if the API structure is the same?
- How do claim 10 (tautomers/salts) and claim 11 (enantiomeric impurities) expand infringement coverage beyond the single enantiomer?
- Which method claims (19–29) are most vulnerable to label carve-outs for a generic?
- What analytical testing parameters most often decide whether DSC/XRD/IR are “substantially the same” for claims 4–9?
References
- United States Patent No. 7,842,687. Claims text provided in prompt.
More… ↓
⤷ Start Trial
|
